LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.
Title: | Armata Clinical Trials Overview for Acute and Chronic Infections with Systemic and Local Phage Administration |
Presenter: | Mina Pastagia, M.D., MS |
Chief Medical Officer | |
Time: | 9:10am – 9:30am EDT (2:10pm – 2:30pm BST) |
For more information or to register: https://www.kisacoresearch.com/events/phage-futures-digital | |
About Phage Futures: Global Digital Summit 2023
Phage Futures: Global Digital Summit 2023 is a stage upon which to initiate all-important discussions and forge partnerships between key stakeholders worldwide. The Summit is the leading platform accelerating the translation of bacteriophages into clinically and commercially viable therapeutics and tangible commercial solutions.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
212-915-2569
| Last Trade: | US$2.40 |
| Daily Change: | -0.02 -0.83 |
| Daily Volume: | 6,900 |
| Market Cap: | US$86.860M |
May 14, 2025 March 20, 2025 March 11, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
